Artigo de periodico

Primary Results of ROSE/TRIO-12, a Randomized Placebo-Controlled Phase III Trial Evaluating the Addition of Ramucirumab to First-Line Docetaxel Chemotherapy in Metastatic Breast Cancer (2015)

• Authors:
  • Mackey, John R.
  • Ramos-Vazquez, Manuel
  • Oleg Lipatov,
  • McCarthy, Nicole
  • Krasnozhon, Dmitriy
  • Semiglazov, Vladimir
  • Manikhas, Alexey
  • Gelmon, Karen A.
  • Konecny, Gottfried E.
  • Webster, Marc
  • Hegg, Roberto
  • Verma, Sunil
  • Gorbunova, Vera
  • Gerges, Dany Abi
  • Thireau, Francois
  • Fung, Helena
  • Simms, Lorinda
  • Buyse, Marc
  • Ibrahim, Ayman
  • Martin, Miguel
• Autor USP: HEGG, ROBERTO - FM
• Unidade: FM
• DOI: 10.1200/JCO.2014.57.1513
• Subjects: NEOPLASIAS MAMÁRIAS; TRATAMENTO (RESULTADOS); METÁSTASE NEOPLÁSICA; ANTINEOPLÁSICOS (CLASSIFICAÇÃO)
• Language: Inglês
• Imprenta:
  • Publisher place: New York
  • Date published: 2015
• Source:
  • Título: Journal of Clinical Oncology
  • ISSN: 0732-183X
  • Volume/Número/Paginação/Ano: v. 33, n. 2, p. 141-148, 2015

Informações sobre a disponibilidade de versões do artigo em acesso aberto coletadas automaticamente via oaDOI API (Unpaywall).
• Este artigo possui versão em acesso aberto
• URL de acesso aberto
• PDF de acesso aberto
• Versão do Documento: Versão publicada (Published version)
• Status: Artigo possui acesso gratuito no site do editor (Bronze Open Access)

---

How to cite

A citação é gerada automaticamente e pode não estar totalmente de acordo com as normas

• ABNT

  MACKEY, John R. et al. Primary Results of ROSE/TRIO-12, a Randomized Placebo-Controlled Phase III Trial Evaluating the Addition of Ramucirumab to First-Line Docetaxel Chemotherapy in Metastatic Breast Cancer. Journal of Clinical Oncology, v. 33, n. 2, p. 141-148, 2015Tradução . . Disponível em: https://doi.org/10.1200/JCO.2014.57.1513. Acesso em: 11 mar. 2026.

• APA

  Mackey, J. R., Ramos-Vazquez, M., Oleg Lipatov,, McCarthy, N., Krasnozhon, D., Semiglazov, V., et al. (2015). Primary Results of ROSE/TRIO-12, a Randomized Placebo-Controlled Phase III Trial Evaluating the Addition of Ramucirumab to First-Line Docetaxel Chemotherapy in Metastatic Breast Cancer. Journal of Clinical Oncology, 33( 2), 141-148. doi:10.1200/JCO.2014.57.1513

• NLM

  Mackey JR, Ramos-Vazquez M, Oleg Lipatov, McCarthy N, Krasnozhon D, Semiglazov V, Manikhas A, Gelmon KA, Konecny GE, Webster M, Hegg R, Verma S, Gorbunova V, Gerges DA, Thireau F, Fung H, Simms L, Buyse M, Ibrahim A, Martin M. Primary Results of ROSE/TRIO-12, a Randomized Placebo-Controlled Phase III Trial Evaluating the Addition of Ramucirumab to First-Line Docetaxel Chemotherapy in Metastatic Breast Cancer [Internet]. Journal of Clinical Oncology. 2015 ; 33( 2): 141-148.[citado 2026 mar. 11 ] Available from: https://doi.org/10.1200/JCO.2014.57.1513

• Vancouver

  Mackey JR, Ramos-Vazquez M, Oleg Lipatov, McCarthy N, Krasnozhon D, Semiglazov V, Manikhas A, Gelmon KA, Konecny GE, Webster M, Hegg R, Verma S, Gorbunova V, Gerges DA, Thireau F, Fung H, Simms L, Buyse M, Ibrahim A, Martin M. Primary Results of ROSE/TRIO-12, a Randomized Placebo-Controlled Phase III Trial Evaluating the Addition of Ramucirumab to First-Line Docetaxel Chemotherapy in Metastatic Breast Cancer [Internet]. Journal of Clinical Oncology. 2015 ; 33( 2): 141-148.[citado 2026 mar. 11 ] Available from: https://doi.org/10.1200/JCO.2014.57.1513

Últimas obras dos mesmos autores vinculados com a USP cadastradas na BDPI:

• Eficacia, tolerabilidade e aceitabilidade do estradiol transdermico no tratamento dos sintomas da menopausa
• Sindrome do climaterio: conceito, importancia e epidemiologia
• Evaluation the predictive value of biomarkers for efficacy outcomes in response to pertuzumab and trastuzumab based therapy: An exploratory analysis of the tryphaena study
• Câncer da mama: quadro clínico, diagnóstico e estadiamento
• Mastite puerperal
• Pertuzumab plus trastuzumab in combination with standard neoadjuvant anthracycline-containing and anthracycline-free chemotherapy regimens in patients with HER2-positive early breast cancer: A randomized phase II cardiac safety study (TRYPHAENA)
• Galactorreia: sindrome hiperprolactinemica
• Genetics of ramucirumab-associated hypertension in the ROSE/TRIO-012 breast cancer trial
• Pertuzumab plus trastuzumab plus docetaxel for metastatic breast cancer
• Everolimus plus endocrine therapy for postmenopausal women with estrogen receptor-positive, human epidermal growth factor receptor 2-negative advanced breast cancer a clinical trial